Nonetheless, six of the 203 children in the watchful waiting group had an exacerbation of their symptoms.

Three patients in the caplacizumab group had an exacerbation, as compared with 11 patients in the placebo group.

Seven recipients either acquired or had an exacerbation of allergic rhinitis, and two recipients without a history of asthma had asthma one year after transplantation.